Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guangdong VTR Bio-Tech Co Ltd
Total Current Assets
Guangdong VTR Bio-Tech Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
|
Total Current Assets
¥1.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
6%
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Assets
¥43.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Current Assets
¥22B
|
CAGR 3-Years
24%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Current Assets
¥4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Assets
¥11.3B
|
CAGR 3-Years
54%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Current Assets
¥2.8B
|
CAGR 3-Years
104%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Guangdong VTR Bio-Tech Co Ltd
Glance View
Guangdong VTR Bio-Tech Co., Ltd. is engaged in the research & development, production, sales and service of biological pharmacy, bio-enzyme preparation, microbe preparation, functional additives and green bio-manufacturing engineering. The company is headquartered in Zhuhai, Guangdong and currently employs 2,807 full-time employees. The company went IPO on 2014-01-28. The firm principally engages in the manufacture and distribution of feedstuff additives, additive pre-mixed feedstuffs, veterinary powders and granules. The Company’s products include enzyme preparations for feedstuffs, including composite enzyme for feedstuffs, phytase for feedstuffs and xylanase for feedstuffs, among others; bio-energy enzyme preparations; spinning enzyme products; food enzyme products; paper making enzyme products; other feedstuff additives, including antioxidants, acidifiers, attractants and fructo oligo saccharides feedstuff additives, as well as veterinary Chinese medicines.
See Also
What is Guangdong VTR Bio-Tech Co Ltd's Total Current Assets?
Total Current Assets
1.2B
CNY
Based on the financial report for Sep 30, 2025, Guangdong VTR Bio-Tech Co Ltd's Total Current Assets amounts to 1.2B CNY.
What is Guangdong VTR Bio-Tech Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
6%
Over the last year, the Total Current Assets growth was -13%. The average annual Total Current Assets growth rates for Guangdong VTR Bio-Tech Co Ltd have been -16% over the past three years , -11% over the past five years , and 6% over the past ten years .
